title: The Early Clinical Response Endpoint: Great Timing by the Food and Drug Administration?
authors.affiliation: Talbot Advisors LLC, Anna Maria, Florida ghtalbot@gmail.com.
authors.forename: George H
authors.initials: GH
authors.lastname: Talbot
mesh_terms: D003872:Dermatitis; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D012867:Skin; D014486:United States Food and Drug Administration
keywords: acute bacterial skin and skin structure infection (ABSSSI); antibiotic development; clinical trial endpoints; community-acquired bacterial pneumonia (CABP); noninferiority trials.